Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced ...

Despite a pair of clinical misfires in 2023, argenx has stuck by the thesis that its star drug Vyvgart, also known as efgartigimod, can tackle a wide array of autoimmune diseases linked to ...

Argenx SE ARGX on Thursday announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART in adults with ocular myasthenia gravis (oMG). It is an autoimmune disorder where ...

Argenx SE (NASDAQ:ARGX) showcased long-term data of Vyvgart (IV: efgartigimod alfa-fcab and SC or Hytrulo: efgartigimod alfa and hyaluronidase-qvfc) demonstrating sustained disease control of ...

Full-year product net sales rose 90% to $4.15 billion from $2.19 billion in 2024, with fourth-quarter sales reaching $1.29 billion versus $737 million in the same period a year earlier. The company ...

Amsterdam, the Netherlands—June 20, 2023—argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...

Delivered $1.1 billion in operating income in 2025, marking first year of operating profitability VYVGART MG label expansion supported by positive ADAPT SERON and OCULUS results; PDUFA target action ...

Efgartigimod alfa, hyaluronidase-qvfc; 1000mg/10000Units (per prefilled syringe), 1008mg/11200Units (per vial); soln for SC inj; preservative-free. Store prefilled syringes or vials refrigerated at ...

BREDA, Netherlands--(BUSINESS WIRE)--Regulatory News: argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund rose 5.39% (Institutional ...